Study Evaluating Safety And Efficacy Of Moroctocog Alfa (AF-CC) In Previously Treated Hemophilia A Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

December 31, 2009

Primary Completion Date

March 31, 2016

Study Completion Date

April 30, 2016

Conditions
Hemophilia A
Interventions
BIOLOGICAL

Moroctocog alfa ( AF-CC)

Dosing is at the discretion of the Investigator

PROCEDURE

Laboratory tests

Factor VIII PK samples, Hematology, Chemistry and Coagulation testing, FactorVIII Inhibitor and Anti Factor VIII antibody

Trial Locations (17)

11000

University Children's Hospital, Belgrade

11009

Hospital Universitario Puerta del Mar, Cadiz

11070

"Mother and Child Health Care Institute of Serbia Dr Vukan Cupic", Belgrade

11407

Hospital Jerez de la Frontera, Jerez de la Frontera

28046

Hospital La Paz, Madrid

35100

Ege University Department of Pediatrics, Pediatric Hematology Division, Izmir

43100

Centro di Riferimento Regionale per la cura dell'Emofilia e delle Malattie Emorragiche Congenite, Parma

50009

Hospital Universitario Miguel Servet, Zaragoza

69063

"Komunalna ustanova Zaporizka oblasna klinichna dytiacha likarnia", Zaporizhzhia

70211

Kuopio University Hospital, Kuopio

79044

"Derzhavna ustanova Instytut patolohii krovi ta transfuziinoi medytsyny Natsionalnoi akademii medych", Lviv

200642

Spitalul Clinic Judetean de Urgenta Craiova, Craiova

0186

LTD Medinvesti- Institute of hematology and transfusiology, Tbilisi

011026

Sanador, Bucharest

171 76

Karolinska Universitetssjukhuset-Solna, Stockholm

01330

Cukurova University Department of Pediatrics, Pediatric Hematology Division, Adana

07059

Akdeniz Universitesi Tip Fakultesi, Antalya

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY